|
|
Post by agedhippie on Aug 20, 2016 18:36:49 GMT -5
The prescription information on Bloomberg terminals isn't "pretty much public information." Symphony charges big bucks for its numbers and to access them on Bloomberg you have to pay a minimum of $25,000 a year for one terminal. If the Rx information was "public," Symphony and Bloomberg couldn't charge so much for it. It's that simple. I understand, but I doubt either symphony or bloomberg make much attempt to trace "leaks" and it seems like there should be a lot of bloomberg terminals available. It doesn't seem like it would be all that hard to find some analyst to peek at MNKD's numbers. They are not about to chase down this, but if Mannkind started pulling the data of a terminal that's commercial use and someone would turn up pretty quick. |
|
|
|
Post by nylefty on Aug 20, 2016 18:44:13 GMT -5
Am curious about decline in TRx as that should be going up as well. I wonder if it is an insurance issue vs user satisfaction. And can mnkd track non renewal persons to get feedback? Renewals are counted as NRx. TRx consists of new NRx and refills. Before the new sales effort the NRx numbers had been declining for months. Therefore it makes sense that the refill numbers will correspondingly decline until the new users are ready to refill. As Liane wrote in the first post on her script count thread: Legend:
NRx = New Prescriptions = New prescriptions includes renewals but does NOT include refills
TRx = Total Prescriptions = Total prescriptions includes refills AND renewals
Read more: mnkd.proboards.com/thread/1742/afrezza-script-counts-symphony-data#ixzz4Hv3dsmTx |
|
|
|
Post by mannmade on Aug 20, 2016 18:47:27 GMT -5
My bad meant refills... Ty
|
|
|
|
Post by nylefty on Aug 20, 2016 19:07:51 GMT -5
Thanks. Even more confused now. Why hasn't MNKD been the one releasing the data all along? Because the numbers were so awful, so embarrassing, so terrible, so discouraging? |
|
|
|
Post by cretin11 on Aug 21, 2016 7:11:40 GMT -5
Biggest NRx number since March? |
|
|
|
Post by audiomr on Aug 21, 2016 16:38:19 GMT -5
This has happened before, and eventually it gets caught up. IMS and Symphony are subscription services, I believe, so the guy who maintains that list must know somebody who has access to the data. If either of those guys is unavailable on Friday, we don't get an update right away. Nothing to get worked up about. The Symphony numbers have been available to anyone who had access to a Bloomberg terminal. Ripano, who posts here, has such access but said yesterday that the Symphony numbers had not been posted. It's as simple as that. As I said earlier, we used to have a source that had access to the IMS numbers, but moderator Liane said some time ago that she no longer had that source. Thanks. That said, this has happened multiple times in the past. |
|
|
|
Post by audiomr on Aug 21, 2016 16:44:28 GMT -5
Thanks. Even more confused now. Why hasn't MNKD been the one releasing the data all along? It's kind of an unusual thing to do. Can't remember seeing a drug company post weekly scrip numbers on a drug. |
|
|
|
Post by tayl5 on Aug 21, 2016 17:16:21 GMT -5
Still hard to know if the increase in NRx this week represents progress or noise but up is up. I'll take it!
|
|
|
|
Post by mnholdem on Aug 21, 2016 17:21:57 GMT -5
Maybe not many scripts, per se, but I've seen a few companies that issue PRs for each major healthplan that begins covering their new drug.
|
|
|
|
Post by peppy on Aug 21, 2016 18:51:22 GMT -5
Thanks. Even more confused now. Why hasn't MNKD been the one releasing the data all along? It's kind of an unusual thing to do. Can't remember seeing a drug company post weekly scrip numbers on a drug. flatrock, really?
audiomr, Mike reads the board. He is investor friendly.
|
|
